On the morning of April 10, Director Shen Yumou, Secretary of the Party Leadership Group and Director of the Hunan Provincial Department of Commerce, led a delegation to visit Jiudian Pharmaceutical for research and guidance. The company's Chairman Zhu, Deputy General Manager and Board Secretary Ms.Zeng, and Director of the Production Center Mr.Xiang accompanied the inspection team.

Director Shen and his delegation focused on inquiring about the structure of the company's export products, export volume, target markets, and export tax rebate policies. Chairman Zhu provided a brief overview of Jiudian Pharmaceutical's operations and its flagship products, noting that its wholly-owned subsidiary, Jiudian Hongyang, has exported its active pharmaceutical ingredients (APIs) and excipients to over 60 countries worldwide, including major markets such as South Korea, India, Poland, Germany, the United States, Mexico, and Brazil, and has established strategic partnerships with several leading international pharmaceutical companies. In 2024, Jiudian Hongyang passed the U.S. FDA's on-site inspection with a "zero 483 defects" record.

Meanwhile, under the combined impact of domestic and international factors, the company currently faces significant challenges in exports, including soaring logistics costs, escalating U.S. Section 301 tariffs, the cancellation of the tax-free policy for small parcels under $800 effective May 2025, and skyrocketing sample customs clearance costs. Additionally, the EU's Critical Medicines Act is driving the risk mitigation of active pharmaceutical ingredients (APIs), while competitors like India enjoy preferential tariffs—all of which are squeezing corporate profit margins.

In response to the aforementioned challenges, Jiudian has put forward five proposals: First, to request coordination and initiation of the U.S.-China pharmaceutical tariff exclusion procedure; Second, to increase support for export credit insurance quotas in emerging markets along the Belt and Road; Third, to provide cost subsidies for enterprises obtaining international high-end certifications such as DMF and CEP; Fourth, to offer incentives for green and low-carbon development to enterprises certified by SBTi; Fifth, to request assistance from the National Medical Products Administration, Changsha Customs, and commerce authorities in assigning customs codes for newly added pharmaceutical sweeteners (such as maltose, sucrose, lactose, etc.).

Director Shen fully affirmed Jiudian's commitment to innovation-driven development and its proactive efforts in expanding international markets. He emphasized that the pharmaceutical industry is a strategically vital sector prioritized for development in Hunan Province. The Provincial Department of Commerce will continue to optimize the business environment, actively coordinate with higher-level authorities and customs inspection agencies, thoroughly address corporate concerns, and provide comprehensive support to help enterprises overcome trade barriers, thereby stabilizing the fundamentals of foreign trade.

Chairman Zhu stated that despite the current complex and volatile international landscape, Jiudian's strategic commitment to global expansion remains unwavering. Leveraging technological innovation and supply chain optimization, and with strong government support, the company will continue to contribute "Hunan's strength" to the global health cause.